Clinical Trials Logo

Retinitis clinical trials

View clinical trials related to Retinitis.

Filter by:

NCT ID: NCT04315025 Completed - Clinical trials for Retinitis Pigmentosa

Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa

RP
Start date: October 7, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The study will perform UC-MSCs and CM transplantation. The first group will be injected by UCMSC+NaCl. the 2nd group will be injected by UC-MSC+CM. the 3rd group will be injected by CM. Each group consists of 6 subjects. all groups will be transplanted via peribulbar route. the dosage of UC-MSC is 1 million cells for each subject. All groups will be observed until 6 months.

NCT ID: NCT04312672 Active, not recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Start date: July 31, 2017
Phase:
Study type: Observational

This is a long-term follow-up study assessing safety of patients for up to 60 months following advanced therapy investigational medicinal product (ATIMP) AAV5-hRKp.RPGR vector in participants with XLRP caused by mutations in RPGR.

NCT ID: NCT04295304 Terminated - Clinical trials for Retinitis Pigmentosa

NR600 System Retinal Prosthesis for Patients With Retinal Degenerative Diseases

NR
Start date: January 17, 2020
Phase: N/A
Study type: Interventional

The study objective is to demonstrate safety of the NR 600 System, and to evaluate the performance of the device in restoring visual activity of daily living in subjects with retinal degenerative diseases and severe visual impairment

NCT ID: NCT04285398 Active, not recruiting - Clinical trials for Retinitis Pigmentosa

Prospective Natural History Study of Retinitis Pigmentosa

PHENOROD2
Start date: February 12, 2020
Phase: N/A
Study type: Interventional

This is natural history study of rods and cones degenerations in patients with Retinitis Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6a or PDE6b gene mutations.

NCT ID: NCT04284293 Recruiting - Clinical trials for Retinitis Pigmentosa

CNS10-NPC for the Treatment of RP

Start date: July 22, 2021
Phase: Phase 1
Study type: Interventional

The investigator is examining the safety of transplanting cells into the subretinal space of patients with Retinitis Pigmentosa (RP). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neuronal cell. The cells are called "CNS10-NPC." The investigational treatment has been tested in animals, but it has not yet been tested in people. In this study, the investigators want to learn if CNS10-NPC cells are safe to transplant into the subretinal space of people.

NCT ID: NCT04281732 Recruiting - Clinical trials for Retinitis Pigmentosa

Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision

Start date: October 1, 2018
Phase:
Study type: Observational

Purpose: To validate a newly developed battery of performance-based tests of visual function to be presented using virtual reality. The tests are intended as potential outcome measures for clinical trials of treatments of eye disease: they measure visual performance in patients with low vision on visual tasks that a relevant for daily life.

NCT ID: NCT04278131 Recruiting - Clinical trials for Retinitis Pigmentosa

BS01 in Patients With Retinitis Pigmentosa

Start date: February 6, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Non-randomized, open label, Phase 1/2 dose escalation study of BS01, a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP).

NCT ID: NCT04252534 Completed - Clinical trials for Retinitis Pigmentosa

Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma

rEMS
Start date: January 1, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to investigate whether natural progression rate can be slowed down with subtenon PRP or PRP application combined with rEMS in retinitis pigmentosa cases.

NCT ID: NCT04238858 Completed - Clinical trials for Retinitis Pigmentosa

Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa

PRP
Start date: September 1, 2016
Phase: N/A
Study type: Interventional

Purpose One of the main reasons for apoptosis and dormant cell phases in degenerative retinal diseases such as retinitis pigmentosa (RP) is growth factor withdrawal in the cellular microenvironment. Growth factors and neurotrophins can significantly slow down retinal degeneration and cell death in animal models. One possible source of autologous growth factors is platelet-richplasma.The purpose of this study was to determine if subtenon injections of autologous platelet-rich plasma (aPRP) can have beneficial effects on visual function in RP patients by reactivating dormant photoreceptors.

NCT ID: NCT04234438 Completed - Clinical trials for Retinitis Pigmentosa

Management of Cystoid Macular Edema Secondary to Retinitis Pigmentosa Via Subliminal Micropulse Yellow Laser

SL-MPL
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Purpose: To investigate the effects of subliminal micropulse yellow laser application on central macular thickness and best corrected visual acuity in cystoid macular edema secondary to retinitis pigmentosa patients.